MA53099A - Formes d'ivosidénib et compositions pharmaceutiques - Google Patents

Formes d'ivosidénib et compositions pharmaceutiques

Info

Publication number
MA53099A
MA53099A MA053099A MA53099A MA53099A MA 53099 A MA53099 A MA 53099A MA 053099 A MA053099 A MA 053099A MA 53099 A MA53099 A MA 53099A MA 53099 A MA53099 A MA 53099A
Authority
MA
Morocco
Prior art keywords
ivosidenib
forms
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
MA053099A
Other languages
English (en)
French (fr)
Inventor
Chong-Hui Gu
Jacob Paul Sizemore
Shijie Zhang
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MA53099A publication Critical patent/MA53099A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA053099A 2018-07-06 2019-07-02 Formes d'ivosidénib et compositions pharmaceutiques MA53099A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862694596P 2018-07-06 2018-07-06

Publications (1)

Publication Number Publication Date
MA53099A true MA53099A (fr) 2021-05-12

Family

ID=69059942

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053099A MA53099A (fr) 2018-07-06 2019-07-02 Formes d'ivosidénib et compositions pharmaceutiques

Country Status (18)

Country Link
US (1) US12264148B2 (enExample)
EP (2) EP4603147A3 (enExample)
JP (2) JP7621242B2 (enExample)
KR (2) KR20250164882A (enExample)
CN (1) CN112367995A (enExample)
AU (2) AU2019299352B2 (enExample)
BR (1) BR112021000156A2 (enExample)
CA (1) CA3103498A1 (enExample)
EA (1) EA202190217A1 (enExample)
IL (3) IL327008A (enExample)
MA (1) MA53099A (enExample)
MX (2) MX2021000068A (enExample)
PH (1) PH12021550017A1 (enExample)
SG (1) SG11202012763TA (enExample)
TW (2) TWI911130B (enExample)
UA (1) UA129800C2 (enExample)
WO (1) WO2020010058A1 (enExample)
ZA (1) ZA202008034B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4010331T (pt) * 2019-08-08 2024-01-08 Servier Lab Um método de preparação do ivosidenib e de um seu intermediário
GB201912411D0 (en) * 2019-08-29 2019-10-16 Johnson Matthey Plc Crystalline forms of ivosidenib
AR133410A1 (es) 2023-08-01 2025-09-24 Servier Lab Cocristal de un inhibidor de idh1, proceso de preparación del mismo, composiciones farmacéuticas del mismo, y métodos de tratamiento que implican el mismo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
CN103459394B (zh) * 2011-04-08 2016-04-27 辉瑞大药厂 结晶和非结晶形式的托法替尼，以及包含托法替尼和渗透增强剂的药物组合物
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
JO3479B1 (ar) * 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب
PH12021551647A1 (en) * 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
SMT202100444T1 (it) * 2014-03-14 2021-09-14 Les Laboratories Servier Sas Composizioni farmaceutiche di composti terapeuticamente attivi
MD3362066T2 (ro) * 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
EP3717470A1 (en) * 2017-11-27 2020-10-07 Assia Chemical Industries Ltd Solid state forms of ivosidenib

Also Published As

Publication number Publication date
MX2021000068A (es) 2021-03-25
TWI911130B (zh) 2026-01-01
TW202019419A (zh) 2020-06-01
IL315423B2 (en) 2026-08-01
TW202543623A (zh) 2025-11-16
JP2021529805A (ja) 2021-11-04
KR102919157B1 (ko) 2026-01-27
CN112367995A (zh) 2021-02-12
EA202190217A1 (ru) 2021-04-16
EP3817744A4 (en) 2022-07-13
IL315423B1 (en) 2026-04-01
CA3103498A1 (en) 2020-01-09
JP7621242B2 (ja) 2025-01-24
TWI902665B (zh) 2025-11-01
AU2019299352B2 (en) 2025-02-27
UA129800C2 (uk) 2025-08-06
AU2025203835A1 (en) 2025-06-12
US20210323944A1 (en) 2021-10-21
IL327008A (en) 2026-05-01
IL279877A (en) 2021-03-01
EP4603147A3 (en) 2025-10-01
BR112021000156A2 (pt) 2021-04-06
KR20210029775A (ko) 2021-03-16
MX2023011687A (es) 2023-10-19
PH12021550017A1 (en) 2021-09-13
KR20250164882A (ko) 2025-11-25
JP2024150784A (ja) 2024-10-23
EP3817744A1 (en) 2021-05-12
AU2019299352A1 (en) 2021-01-07
WO2020010058A1 (en) 2020-01-09
US12264148B2 (en) 2025-04-01
SG11202012763TA (en) 2021-02-25
IL315423A (en) 2024-11-01
ZA202008034B (en) 2021-10-27
EP4603147A2 (en) 2025-08-20

Similar Documents

Publication Publication Date Title
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
MA55206A (fr) Polyribonucléotides circulaires et compositions pharmaceutiques associées
EP3817722A4 (en) PHARMACEUTICAL COMPOSITIONS WITH MELOXICAM
EP3548000A4 (en) PHARMACEUTICAL COMPOSITIONS OF ATROPINE
EP3880688A4 (en) OLIGOSACCHARID PREPARATIONS AND COMPOSITIONS
EP3897593A4 (en) CANNABINOID FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS
EP3803403A4 (en) COMPOSITIONS AND METHODS FOR IMAGING
IL280475A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MA55015A (fr) Formulations pharmaceutiques
EP3474844A4 (en) PHARMACEUTICAL FOR EVAPORATING AND SMOKING
EP3906019C0 (en) Pharmaceutical compositions of furosemide
EP4031520A4 (en) IMAGING AND THERAPEUTIC COMPOSITIONS
EP3826673A4 (en) COMPOSITIONS AND METHODS FOR IMAGING
EP3914234A4 (en) Pharmaceutical compositions
DK3981390T3 (da) Farmaceutisk lacosamid-sammensætning og farmaceutisk præparat deraf
MA53333A (fr) Formulations pharmaceutiques d'anticorps masqués
MA55568A (fr) Compositions pharmaceutiques orodispersibles d'apixaban
EP3946316A4 (en) PHARMACEUTICAL CANNABIDIOL COMPOSITIONS
EP3773654C0 (en) POLYPHARMACEUTICAL DRUG COMPOSITIONS AND ASSOCIATED METHODS
EP3452441A4 (en) ALPHA-TRUXILLINIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
EP3664797A4 (en) NR4A1 LIGANDS, PHARMACEUTICAL COMPOSITIONS, AND RELATED METHODS OF USE
IL282157A (en) Compounds and therapeutic uses thereof
EP4015001A4 (en) Oral pharmaceutical composition
EP3790543A4 (en) COMPOSITIONS AND DOSAGE FORMS FOR ORAL ADMINISTRATION
EP4034113A4 (en) THERAPEUTIC FORMULATIONS AND THEIR USES